Optic Neuritis After COVID-19 Vaccination: A Case Series and a Review of Literature

Sheng-Chi Yang,Yu-Kuei Lee,Ming-Tsung Chuang,Huai-Wen Hsu,Hsu-Yang Chang,Yi-Sheng Chang
DOI: https://doi.org/10.1097/wno.0000000000002161
IF: 1.136
2024-08-22
Clinical Neuropathology
Abstract:Background: The coronavirus disease (COVID-19) pandemic broke out in March 2020, causing tremendous damage to public health and more than 6 million deaths. After authorization for the emergency use of COVID-19 vaccines, various adverse events have been reported, including optic neuritis. COVID-19 vaccination was implemented in Taiwan in March 2021. Methods: We report patients who developed optic neuritis after COVID-19 vaccination at one university-affiliated tertiary hospital, between March 2021 and December 2022. We also provided a literature review of optic neuritis cases after COVID-19 vaccination. Results: Five patients who developed optic neuritis after COVID-19 vaccination have been identified. Four brands of vaccine used were as follows: Moderna, Pfizer-BioNTech, Medigen, and Oxford AstraZeneca. Optic neuritis developed after the first dose of vaccination in 4 patients, whereas in 1 patient, it developed after the second shot. In the 3 patients with poor initial visual acuity, intravenous methylprednisolone pulse therapy achieved substantial improvement. Conclusions: Optic neuritis is a rare but potentially vision-threatening adverse effect of COVID-19 vaccination. We suggest early diagnosis and treatment to maximize visual outcomes.
pathology,clinical neurology
What problem does this paper attempt to address?